Two Novel Product Platforms

FLAG Therapeutics, Inc. is an early-stage oncology company focused on the development of therapies based on two investigational product platforms:

  • Anti-angiogenic/Anti-tubulin (AA/AT) Compounds:  Investigational water-soluble small molecule drugs designed to harness the power of two well-understood anti-cancer activities into one molecular function.
     
  • Folate-targeted Anti-cancer (FTAC) Compounds:  Investigational water-soluble small molecule drugs designed to specifically target and destroy tumor cells.